Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-15
2005-02-15
Jones, Dwayne (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S014000, C546S048000
Reexamination Certificate
active
06855720
ABSTRACT:
(20S) esters of camptothecin analogs are provided. The compounds are (20S) esters of an aminoalkanoic acid or an imidoalkanoic acid and camptothecin, which is optionally substituted at the 7, 9, 10, 11, and 12 positions of the camptothecin ring. The compounds are useful for treating cancer.
REFERENCES:
patent: 4399282 (1983-08-01), Miyasaka et al.
patent: 4943579 (1990-07-01), Vishnuvajjala et al.
patent: 5916896 (1999-06-01), Wall et al.
patent: 5965566 (1999-10-01), Greenwald et al.
patent: 6028078 (2000-02-01), Hausheer et al.
patent: 6040313 (2000-03-01), Wall et al.
patent: 6057303 (2000-05-01), Haridas et al.
patent: 6096336 (2000-08-01), Cao et al.
patent: 6113906 (2000-09-01), Greenwald et al.
patent: 6114529 (2000-09-01), Kawaguchi et al.
patent: 6120793 (2000-09-01), Cao et al.
patent: 6127355 (2000-10-01), Greenwald et al.
patent: 6153655 (2000-11-01), Martinez et al.
patent: 6207832 (2001-03-01), Curran et al.
patent: 6339091 (2002-01-01), Bigg et al.
patent: 6350756 (2002-02-01), Yang et al.
patent: 6403604 (2002-06-01), Yang et al.
patent: 0 861 842 (1998-09-01), None
patent: WO 9510304 (1995-04-01), None
patent: WO 9626950 (1996-09-01), None
patent: WO 9719085 (1997-05-01), None
patent: WO 9728165 (1997-08-01), None
patent: WO 9813059 (1998-04-01), None
patent: WO 9814459 (1998-04-01), None
patent: WO 9828304 (1998-07-01), None
patent: WO 9835940 (1998-08-01), None
patent: WO 9851703 (1998-11-01), None
patent: WO 9917805 (1999-04-01), None
patent: WO 0066127 (2000-11-01), None
patent: WO 0067801 (2000-11-01), None
patent: WO 03014069 (2003-02-01), None
Stein, J., Editor-in-Chief, Internal Medicine, 4th Edition, Chapters 71 and 72, 1994.*
Bom, David et al., “The Novel Silatecan 7-tert-Butyldimethylsilyl-10-hydroxycamptothecin Displays High Lipophilicity, Improved Human Blood Stability, and Potent Anticancer Activity,” J. Med. Chem., 2000, v. 43, pp. 3970-3980.
Cao, Zhisong et al., “Alkyl Esters of Camptothecin and 9-Nitrocamptothecin: Synthesis, in Vitro Pharmacokinetics, Toxicity, and Antitumor Activity,” J. Med. Chem., 1998, v. 41, pp. 31-37.
Dallavalle, Sabrina et al., “Novel 7-Substituted Camptothecins with Potent Antitumor Acitvity,” J. Med Chem., 2000, v. 43, pp. 3963-3969.
Del Poeta, Maurizio et al., “Comparison of In Vitro Activities of Camptothecin and Nitidine Derivatives against Fungal and Cancer Cells,” Antimicrobial Agents and Chemotherapy, Dec. 1999, v. 43, n. 12, pp. 2862-2868.
Keskin et al., Anti-Cancer Drug Des. (2000), 15(2):79-98 Abstract.
Kingsbury, William D. et al., “Synthesis of Water-Soluble (Aminoalkyl)camptothecin Analogues: Inhibition of Topoisomerase I and Antitumor Activity,” J. Med. Chem., 1991, v. 34, pp. 98-107.
O'Leary, J. et al., “Camptohecins: a Review of their Development and Schedules of Administration,” European Journal of Cancer, 1998 v. 34, n. 10, pp. 1500-1508.
Saltz L. et al., “CPT-11 (Irinotecan) and 5-Fluorouracil: a Promising Combination for Therapy of Colorectal Cancer”, European Journal of Cancer, 1996, vol. 32A, No. Suppl. 3, pp. 524-531.
Singer et al., “Conjugation of Camptothecins to Poly-(L-Glutamic Acid)”, Annals of the New York Academy of Sciences, 2000, vol. 922, pp. 136-150.
Sawada, Seigo et al., “Chemical Modification of an Antitumor Alkaloid Camptothecin: Synthesis and Antitumor Acitivity of 7-C-Substituted Camptothecins,” Chem. Pharm. Bull., 1991, v. 39, n. 10, pp. 2574-2580.
Sawada, Seigo et al., “Synthesis and Antitumor Activity of 20(S)-Camptothecin Derivatives: Carbamate-Linked, Water-Soluble Derivatives of 7-Ethyl-10-hydroxycamptothecin,” Chem. Pharm. Bull., 1991, v. 39, n. 6, pp. 1446-1454.
Takayama, Hiromitsu et al., “Synthesis of a New Class of Camptothecin Derivatives, the Long-Chain Fatty Acid Esters Of 10-Hydroxycamptothecin, as a Potent Prodrug Candidate, and their In Vitro Metabolic Conversion by Carboxylesterases,” Bioorganic & Medicinal Chemistry Letters 8, 1998, pp. 415-418.
Wall, Monroe E. et al., “Camptothecin and Taxol: Discovery to Clinic—Thirteenth Bruce F. Cain Memorial Award Lecture,” Cancer Research 55, Feb. 15, 1995, pp. 753-760.
Wall, Monroe E. et al., “Plant Antitumor Agents. 30.labSynthesis and Structure Activity of Novel Camptothecin Analogs,” J. Med. Chem., 1993, v. 36, pp. 2689-2700.
Zhao, Rulin et al., “Synthesis, topoisomerase I inhibitory activity and in vitro cytotoxicity of camptothecin derivatives bearing five-membered heterocycle containing 10-substituents,” Anti-Cancer Drug Design, 1998, v. 13, pp. 145-157.
XP 002033248, Abstract, WPI, vol. 46, No. 89.
XP 002033250 Abstract, WPI, vol. 45, No. 89.
Bomgaars, et al., “The Development of Camptothecin Analogs in Childhood Cancers,” Oncolgist 6:506-516 (2001).
Lerchen, “Milestones in Camptothecin Research,” Drugs of the Future 27:869-876 (2002).
Garcia-Carbonero et al., “Current Perspectives on the Clinical Experience, Pharmacology and Continued Development of the Camptothecins”,Clinical Cancer Research, Mar. 2002, vol. 8, 641-661.
Shabat D et al., “Multiple event activation of a generic prodrug trigger by antibody catalysis”, Proceedings of the National Academy of Sciences of USA, 96:6925-6930, Jun. 1999.
Keskin, O. et al., “Characterization of anticancer agents by their growth inhibitory activity and relationships to mechanism of action and structure”, Anti Cancer Drug Design, 15:2:78-98 (2000).
Maliepaard et al., “Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918,”Clinical Cancer Research7:935-941, 2001.
Nomoto et al., “Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f,”Jpn. J. Cancer Res.89:1179-1186, 1998.
Perego et al., “A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line,”Cancer Research61:6034-6037, 2001.
Pollack et al., “Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo,” Cancer Research 59:4898-4905, 1999.
California Pacific Medical Center
Catholic Healthcare West
Cooley & Godward LLP
Jones Dwayne
LandOfFree
Nitrogen-based camptothecin derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitrogen-based camptothecin derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitrogen-based camptothecin derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3486757